Nkarta, Inc. — Director's Dealing 2020

Jul 10, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Nkarta, Inc. (NKTX)
CIK: 0001787400
Period of Report: 2020-07-09

Reporting Person: GLAXOSMITHKLINE PLC (Director, 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (525499)		Indirect
Series B Preferred Stock	$		Common Stock (1712810)		Indirect

Footnotes

F1: The Series A Preferred Stock is convertible at a conversion rate equal to one share of Common Stock per 3.7 shares of Series A Preferred Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F2: The Series B Preferred Stock is convertible at a conversion rate of Common Stock per 3.7 shares of Series B Preferred Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

F3: Gives effect to the one-for-3.7 reverse stock split of the Issuer's common stock and a proportional adjustment to the conversion ratio of the Series A Preferred Stock and Series B Preferred Stock, effective on July 1, 2020.

F4: The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.